Increased fluid intake has minimal effect on male bladder function
Increased water intake may improve some aspects of bladder function in older men, but the effects are too small to be clinically relevant, according to a study by Dutch researchers.
Increased water intake may improve some aspects of bladder function in older men, but the effects are too small to be clinically relevant, according to a study by Dutch researchers.
A total of 141 men, 55 to 75 years of age, with moderate lower urinary tract symptoms participated in the randomized, placebo-controlled trial (Urology 2006; 68:1031-6). The experimental group drank an additional 1.5 liters of water daily, and the control group consumed one tablespoon of placebo syrup daily.
After 6 months, the team evaluated bladder contractility, voided volumes, and the severity of lower urinary tract symptoms. Increases in water consumption were measured.
Water consumption in the intervention group increased by 359 mL (95% confidence interval: 171-548) per 24 hours compared with the control group. At 6 months, no statistically significant effect was found in the maximum flow rate (0.9 mL/s, 95% CI: −0.4-2.2) of the intervention group compared with that of the placebo group. A statistically significant effect was found for bladder pressure (20 cm H2O, 95% CI: 6-34) and bladder wall stress (1.9 N/cm2, 95% CI: 6-34). In addition, the experimental group had greater maximum (44 mL, 95% CI: −1-90) and average (26 mL, 95% CI: 1-51) voided volumes per urination.
The subjective effect parameters improved in both groups, but no statistically significant differences were found between the two groups, the authors reported.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
